This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sonnet BioTherapeutics Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sonnet BioTherapeutics Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Seeking Alpha • Oct 04

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Clinical-stage drugs company Sonnet BioTherapeutics (NASDAQ:SONN) said it has received notice from the Nasdaq over regaining compliance with the minimum bid price requirement. The notice was received on Aug. 22. The company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. SONN had met the requirement on Sep. 30. Shares were trading -1.35% pre-market. Source: Press Release

Seeking Alpha • Sep 16

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

In a bid to maintain a Nasdaq's minimum price requirement, Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has announced plans of 1-for-14 reverse stock split of its shares on Friday The stock is slated to begin trading on split adjusted basis from Sept. 19, 2022. SONN shares are up 21% pre-market.

Seeking Alpha • Jul 22

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Sonnet BioTherapeutics (NASDAQ:SONN) said a phase 1b/2a trial of SON-080 was authorized to begin in Australia in patients with persistent chemotherapy-induced peripheral neuropathy (CIPN). Peripheral neuropathy is damage to the nerves outside the brain and spinal cord (peripheral nerves) causing weakness and pain, usually in the hands and feet. It can also affect digestion, urination and circulation. Chemotherapy can also cause peripheral nerve damage in patients. SON-080 is a proprietary version of recombinant human Interleukin-6 (rhIL-6), the company noted in a July 22 press release. The study, dubbed SB211, is aimed to provide safety data compared to previous IL-6 products, along with preliminary efficacy. "Interleukin-6 has been extensively studied in cancer patients in the past, so the use of SON-080 in CIPN is expected to provide similar safety, PK, and PD results at low doses," said Sonnet's Chief Medical Officer Richard Kenney. The company noted that recruitment has begun and dosing is expected to begin imminently.

Analysis Article • Dec 19

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sonnet BioTherapeutics Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:SONN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2025	1	N/A	N/A	N/A	1
6/30/2025	1	-14	-10	-10	N/A
3/31/2025	1	-13	-12	-12	N/A
12/31/2024	1	-9	-8	-8	N/A
9/30/2024	0	-7	-9	-9	N/A
6/30/2024	0	-8	-10	-10	N/A
3/31/2024	0	-8	-13	-13	N/A
12/31/2023	0	-14	-19	-19	N/A
9/30/2023	0	-19	-22	-21	N/A
6/30/2023	0	-23	-23	-23	N/A
3/31/2023	0	-27	-25	-25	N/A
12/31/2022	0	-29	-26	-26	N/A
9/30/2022	0	-30	-29	-28	N/A
6/30/2022	1	-29	-28	-27	N/A
3/31/2022	1	-27	-26	-25	N/A
12/31/2021	1	-25	-26	-26	N/A
9/30/2021	0	-25	-23	-23	N/A
6/30/2021	N/A	-67	-22	-22	N/A
3/31/2021	N/A	-73	-23	-23	N/A
12/31/2020	N/A	-69	-19	-19	N/A
9/30/2020	N/A	-66	-16	-16	N/A
6/30/2020	N/A	-20	-11	-11	N/A
3/31/2020	N/A	-9	-5	-5	N/A
12/31/2019	N/A	-7	-4	-4	N/A
9/30/2019	N/A	-5	-2	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SONN's forecast earnings growth is above the savings rate (3.3%).

Earnings vs Market: Insufficient data to determine if SONN's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if SONN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SONN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SONN's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SONN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/03 09:35
End of Day Share Price	2025/12/02 00:00
Earnings	2025/06/30
Annual Earnings	2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sonnet BioTherapeutics Holdings, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Keay Nakae	Chardan Capital Markets, LLC

This company is no longer active

Sonnet BioTherapeutics Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$1.95 loss

Consensus revenue estimates increase by 42%, EPS downgraded

Price target decreased by 13% to US$10.35

Consensus revenue estimates decrease by 50%, EPS upgraded

Price target decreased to US$25.00

Consensus forecasts updated

Recent updates

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Sep 26, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Expansion of Its Clinical Study of Patients with Platinum-Resistant Ovarian Cancer (PROC) (SB221)

Sonnet BioTherapeutics Holdings, Inc. Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Hyperliquid Strategies Inc entered into a definitive agreement to acquire Sonnet BioTherapeutics Holdings, Inc. (NasdaqCM:SONN) in a reverse merger transaction.

Sonnet BioTherapeutics Holdings, Inc. Announces CEO Changes

Sonnet BioTherapeutics Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet Bio Therapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of Its Il-18 Binding Protein Resistant Variant Protein

Sonnet Biotherapeutics Holdings, Inc. Presents Compilation of Data Highlighting the Potential of Son-1010 as A Monotherapy or A Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet Biotherapeutics Holdings, Inc. Announces Proprietary Antibody Drug Conjugate Platform Is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Holdings, Inc. Announces Chief Financial Officer Changes, Effective February 21, 2025

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Holdings, Inc. announced that it has received $3.918 million in funding

Sonnet BioTherapeutics Holdings, Inc. Auditor Raises 'Going Concern' Doubt

Sonnet BioTherapeutics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.420243 million.

Sonnet BioTherapeutics Holdings, Inc. Announces Publication Detailing Discovery and Development of SON-1010, Albumin-Binding IL-12 Fusion Protein, Demonstrating its Mechanism of Action

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Sonnet BioTherapeutics Holdings, Inc. has filed a Follow-on Equity Offering.

Sonnet BioTherapeutics Regains Compliance with Nasdaq

Sonnet BioTherapeutics Holdings, Inc Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Nasdaq Hearings Panel Grants Sonnet BioTherapeutics Holdings, Inc. an Exception Until October 15, 2024 to Regain Compliance with the $1.00 Minimum Bid Price Requirement

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Consensus EPS estimates upgraded to US$1.95 loss

Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting

Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target

Consensus revenue estimates increase by 42%, EPS downgraded

Second quarter 2024 earnings released: EPS: US$0.079 (vs US$7.55 loss in 2Q 2023)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$1.82 loss in 3Q 2022)

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023

Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab

Founder recently bought US$83k worth of stock

Price target decreased by 13% to US$10.35

Consensus revenue estimates decrease by 50%, EPS upgraded

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $14.999777 million.

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010